Wegovy® tablets and nausea

Four sources, one tablet trial

Every tablet-specific nausea number traces back to a single study. The US label calls it Study 7: 204 adults without type 2 diabetes took the 25 mg tablet for up to 64 weeks, followed by seven weeks off treatment; their average starting weight was 106.4 kg and 76% were women. ^[1] The trial is better known as OASIS 4. Its peer-reviewed report gives one digestive figure in the abstract: gastrointestinal adverse events of any kind in 74.0% on the tablet and 42.2% on placebo. ^[4]

The US label does not print a nausea figure for the tablet. Its weight-reduction table (Table 3) pools three trials of the 2.4 mg injection, and for the tablet the label adds a single sentence: the types and frequency of common reactions were similar to that table. ^[1] The EU product information goes further and quotes OASIS 4 directly. The ClinicalTrials.gov record holds the sponsor’s own counts; it is an official registry, but its results are not peer reviewed and list only non-serious events reported by at least 5% of either group. ^[2][3]

Which weeks are most likely

Dose steps are where the documents place the problem. The tablet starts at 1.5 mg once a day for days 1 to 30, moves to 4 mg for days 31 to 60 and 9 mg for days 61 to 90, and reaches the 25 mg maintenance strength from day 91. ^[1] The EU version describes the same climb in four-week blocks and allows a person to stay at the previous strength if needed. ^[2] Both say nausea and most other digestive reactions were seen mainly while the dose was being raised, and the EU patient leaflet adds that they usually fade with time. ^[2]

The manufacturer’s pill guide says the same in plainer words: side effects can be more noticeable when a new strength starts, and a prescriber may keep someone on one strength for longer than 30 days. ^[8] None of the sources breaks tablet nausea down by step or by month, so there is no published answer to whether the 4 mg or the 9 mg month is harder.

Safety databases add a rough sense of timing. A study of US FDA adverse event reports from 2018 to mid-2023 found that digestive complaints began a median of 4 days after starting oral semaglutide, the same as for the injection. ^[6] Those reports end while OASIS 4 was still running (it finished in 2024), so they cannot include the marketed 25 mg weight tablet, and voluntary reports cannot give a rate or prove cause. ^[3][6]

The empty-stomach routine and your stomach

The tablet comes with a morning ritual that the pen does not have. The label asks for one tablet on waking, before any food, swallowed whole with plain water only and no more than 4 ounces of it, and then a gap of at least 30 minutes before food, any other drink or another oral medicine. ^[1] The EU text specifies a fast of at least eight hours beforehand and up to half a glass (120 mL) of water. ^[2]

It is tempting to think the wait itself brings on queasiness, or eases it. The documents say neither. They explain the routine in terms of absorption: in studies, more semaglutide was absorbed after a longer fast following the dose, a large glass of water (240 mL) lowered absorption compared with a small one, and there was no clinically meaningful difference between 50 and 120 mL. ^[1] Swallowing the tablet together with five other tablets cut semaglutide exposure by about a third. ^[2] The routine is about getting the dose in, not about comfort, and changing it on your own could change how much medicine you absorb.

Comfort comes in with the first meal after the window. The manufacturer’s nausea tips, written for Wegovy® in general, include bland low-fat foods such as crackers, toast or rice, foods with water in them such as soup, eating slowly, fresh air, and avoiding greasy food or lying down after eating. ^[7] A medicine for nausea taken by mouth counts as another oral medicine, so under the label it would come after the 30 minutes; whether to use one at all is a question for your pharmacist or prescriber. ^[1]

Blood levels, variability and the injection

The tablet delivers semaglutide less evenly than the pen. The label estimates that 90% of people on the 25 mg tablet had average concentrations between 27 and 186 nmol/L, against 51 to 110 nmol/L on the 2.4 mg weekly injection. ^[1] The EU document adds that only about 1–2% of the semaglutide in a tablet is absorbed and that absorption is highly variable and can be minimal. ^[2]

Does more variability mean more nausea? A modelling analysis by Novo Nordisk scientists and two trial investigators pooled data from the tablet and injection programmes. Nausea and vomiting reports climbed as blood levels rose, but the curve flattened across the levels the 25 mg tablet produces, and the tablet’s higher variability did not visibly change that relationship. The average nausea rate was slightly higher with the tablet than with the injection, with confidence intervals that overlapped substantially. ^[5] This is a model fitted to trial data, not a head-to-head trial.

The trial-level totals point the same way: digestive adverse events of any kind in 74.0% on the tablet versus 42.2% on placebo in OASIS 4, and 73% versus 47% in the injection trials behind Table 3. ^[4][1] Different studies, placebo groups and counting rules mean those totals cannot be ranked against each other.

What may be going on in the body

• Supported by the label: semaglutide slows stomach emptying. The tablet section of the EU document calls this a minor delay just after meals and lists delayed gastric emptying itself as an uncommon reaction. ^[1][2]
• Supported by the timing: reactions cluster around dose increases, which is why both documents use a stepped start. ^[1][2]
• Proposed, not shown for nausea: the GLP-1 receptor sits in brain areas that regulate appetite, and animal work shows semaglutide acts there. Whether the same pathways produce the queasy feeling in a given person has not been demonstrated. ^[2]
• Not specific to Wegovy®: MedlinePlus lists glutide medicines among many everyday causes of nausea. ^[10]

When the tablet may not be the cause

A queasy morning has plenty of other explanations. MedlinePlus lists stomach infections and food poisoning, reflux, migraine, motion sickness, early pregnancy, heavy cannabis use and slow stomach emptying, and notes that nausea can be an early sign of appendicitis, a bowel blockage or an ulcer. ^[10]

Some of these overlap with the Wegovy® documents. The label does not recommend the medicine in severe gastroparesis, and the EU text says people with a history of gastroparesis, or with moderately reduced kidney function, may have more digestive effects. ^[1][2] Pregnancy is the other one to keep in mind: the Medication Guide asks you to tell your provider if you are or may be pregnant and to stop Wegovy® two months before a planned pregnancy, and the EU leaflet advises contraception during treatment. ^[1][2]

Questions to take to your prescriber

• Whether smaller, more frequent meals, stopping as soon as you feel full, or avoiding fatty, fried or spicy food would suit you; the manufacturer suggests asking exactly these. ^[7]
• How to keep fluids up without feeling over-full. MedlinePlus describes frequent small sips of clear liquid as part of home care once the cause is known. ^[7][10]
• Whether the next 30-day step should wait. The label lets a prescriber delay escalation when a strength is not tolerated. ^[1]
• What the options are if 25 mg itself is the problem. The label describes considering a switch to the 1.7 mg weekly injection; the EU text allows staying at the previous tablet strength. ^[1][2]
• Whether anything else you take could add to the nausea; the label asks you to list every medicine, including over-the-counter products, vitamins and herbal supplements. ^[1]

Wegovy® and Rybelsus® are registered trademarks of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.

When to get help